Zeneca management shift means strategy continues
Article Abstract:
Zeneca Group PLC's decision to promote Dr. Tom McKillop as chief executive officer of the firm in 1999 practically guarantees the continuance of the firm's strategy, which has been based on organic growth and bolt-on acquisitions. It also particularly underscores the firm's strategy to remain independent amid recent megamergers in the pharmaceutical industry. McKillop will succeed Sir David Barnes who held the post since the 1993 dissolution of the merger of Imperial Chemical Industries PLC's (ICI) drug and agrochemical divisions.
Comment:
Decision to promote Tom McKillop as CEO of co in 1999 practically guarantees the continuance of co's strategy
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Roche research chief bets firm's future on genetic research
Article Abstract:
Roche's new research director, Dr. Jonathan Knowles, intends to take the firm into what is considered as the future of the industry, disease management. Knowles, a geneticist, is the first non-organic chemist to head the drug maker's research arm, a move that is seen as an indication of the firm's new direction towards disease treatment. The approach is expected to produce drugs that are tailored to a particular individual's genetic makeup thereby improving on the current wasteful process of prescribing medicine.
Comment:
Its new research director, Dr Jonathan Knowles, intends to take the firm into the future of the industry, disease management
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Medeva's top drug slips, spurring 46% profit plunge
Article Abstract:
Medeva PLC posted a decline of 46% in its profits for the first-half of 1999. The company's profits fell to 19.7 million pound sterling (30.1 million euros) during the period. During the same period in 1998, Medeva's profits were 36.7 million pound sterling. The company's revenues also fell 11% to 126 million pound sterling. During the 1998 first-half, revenues were 141 million pound sterling.
Comment:
Posts decline of 46% in profits for first-half of 1999
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Japan targets Asian palates: Hong Kong diners embrace octopus dumplings. Good fun, Japanese-style
- Abstracts: A new assignment rule to improve seed points algorithms for the continuos k-center problem. A continuous location model for siting a non-noxious undesirable facility within a geographical region
- Abstracts: Efficiency in constrained continuous location. Coincidence conditions in multifacility location problems with positive and negative weights
- Abstracts: Investment remains sluggish. Malaysia alters tax rule. Malaysia may privatize funds
- Abstracts: Hamburger craze bites Hong Kong. Fees to go? McDonald's pays in order to stay in Beijing. Hamburger craze bites Hong Kong: Snoopy figurines land McDonald's in a consumer dogfight